MedTrace Logo

Surufatinib in G3 Neuroendocrine Tumors

NCT05973968 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2023-08-04

No results posted yet for this study

Summary

The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are:

* To evaluate the efficacy and safety of surufatinib in the treatment of second-line and posterior-line in G3 neuroendocrine tumors.
* To explore the predictive value of blood perfusion parameters in curative effect.

Participants will be given surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity.

Conditions

  • Neuroendocrine Tumor Grade 3

Interventions

DRUG

Surufatinib

Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Yantai Yuhuangding Hospital

    collaborator OTHER

  • Weifang People's Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-06-30
Completion
2025-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05973968 on ClinicalTrials.gov